Solution Structure of a Zn(II) Bleomycin A₅-d(CGCTAGCG)₂ Complex

Richard A. Manderville, Jeffrey F. Ellena, and Sidney M. Hecht^{*}

> Departments of Chemistry and Biology University of Virginia, Charlottesville, Virginia 22901

> > Received July 26, 1994

The bleomycins (BLMs)¹ are clinically used antitumor antibiotics² that bind and degrade DNA³ and RNA⁴ selectively in the presence of O₂ and certain metals. Bleomycin contains at least two functional domains: a metal binding domain required for reductive activation of O21 and DNA binding5 and a DNA binding domain comprised of the bithiazole (Bit) and C-terminal substituent (spermidine (Sp) in BLM A₅, Figure 1).

NMR spectroscopy has been used to investigate the nature of BLM binding with various metal ions⁶ and DNA.⁷ However, the absence of intermolecular NOEs7 and the continuing uncertainty concerning the exact metal ligands⁶ have precluded definition of the nature of DNA binding by metallobleomycins. Presently, we use Zn(II) BLM A₅ and a DNA octanucleotide $(d(CGCTAGCG)_2)$ that is a particularly efficient substrate for BLM⁸ to address the issue of DNA binding. The key observations of six intermolecular BLM-DNA NOEs and the lack of perturbation of DNA sequential connectivities upon BLM binding⁹ have permitted us to utilize molecular dynamics calculations to develop a model of DNA binding by Zn(II) BLM A5.

Proton assignments for Zn(II)·BLM A5 alone and free d(CGCTAGCG)2¹⁰ were established by means of DQF-COSY¹¹ and NOESY¹² experiments (supplementary material, Tables 1 and 2). Zn(II)•BLM A₅ binding did not disrupt the C_2 symmetry of the duplex, indicative of fast exchange; consistent with this, only one set of drug resonances was observed. In addition, it

(2) Bleomycin Chemotherapy; Sikic, B. I., Rozencweig, M., Carter, S.

(a) D'Andrea, A. D.; Haseltine, W. A. Proc. Natl. Acad. Sci. U.S.A.
(b) Carter, B. J.; Haseltine, W. A. Proc. Natl. Acad. Sci. U.S.A.
1978, 75, 3608. (b) Takeshita, M.; Grollman, A. P.; Ohtsubo, E.; Ohtsubo, H. Proc. Natl. Acad. Sci. U.S.A.
(4) (a) Carter, B. J.; de Vroom, E.; Long, E. C.; van der Marel, G. A.; van Boom, J. H.; Hasht S. M. Brac, Natl. Acad. Sci. U.S.A.

(a) Catch D. 3., de Vioni, E., Eong, E. C., Vali dei Malel, G. A.,
 van Boom, J. H.; Hecht, S. M. *Proc. Natl. Acad. Sci. U.S.A.* 1990, 75,
 5683. (b) Hecht, S. M. *Bioconjugate Chem.*, in press.
 (5) Carter, B. J.; Murty, V. S.; Reddy, K. S.; Wang, S.-N.; Hecht, S. M.
 J. Biol. Chem. 1990, 265, 4193.

J. Biol. Chem. 1990, 265, 4193.
(6) (a) Oppenheimer, N. J.; Rodriguez, L. O.; Hecht, S. M. Biochemistry 1979, 18, 3439. (b) Oppenheimer, N. J.; Rodriguez, L. O.; Hecht, S. M. Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 5616. (c) Sheridan, R. P.; Gupta, R. K. J. Biol. Chem. 1981, 256, 1242. (d) Akkerman, M. A. J.; Haasnoot, C. A. G.; Hilbers, C. W. Eur. J. Biochem. 1988, 173, 211. (e) Akkerman, M. A. J.; Neijman, E. W. J. F.; Wijmenga, S. S.; Hilbers, C. W.; Bermel, W. J. Am. Chem. Soc. 1990, 112, 7462. (f) Xu, R. X.; Nettesheim, D.; Otyos J. D.: Petering D. H. Biochemistry 1994, 33, 907. Otvos, J. D.; Petering, D. H. Biochemistry 1994, 33, 907.
 (7) (a) Glickson, J. D.; Pillai, R. P.; Sakai, T. T. Proc. Natl. Acad. Sci.

U.S.A. **1981**, 78, 2967. (b) Gamcsik, M.P.; Glickson, J. D.; Zon, G. J. Biomol. Struct. Dyn. **1990**, 7, 1117. (c) Hiroaki, H.; Nakayama, T.; Ikehara, M.; Uesugi, S. Chem. Pharm. Bull. **1991**, 39, 2780.

(8) Fe•BLM cleaves d(CGCTAGCG)₂ with selectivity for cytidine₃ and cytidine⁷. Van Atta, R. B.; Long, E. C.; Hecht, S. M.; van der Marel, G. A.; van Boom, J. H. J. Am. Chem. Soc. **1989**, 111, 2722.

A., van Booin, J. H. J. Am. Chem. Soc. 1969, 111, 2122.
(9) NMR experiments used a General Electric Omega 500 spectrometer. The 1:1 Zn(II) BLM As-d(CGCTAGCG)₂ complex (4.2 mM) was studied at 15 and 35 °C in D₂O and H₂O, pH 7.0, containing 20 mM NaCl. (10) d(CGCTAGCG)₂ exists as a B-form duplex at concentrations similar to those utilized here (Pieters, J. M. L.; de Vroom, E.; van der Marel, G. A.; van Boom, J. H.; Altona, C. Eur. J. Biochem. 1989, 184, 415).
(11) Double guartum filtered IH-appreciated genetoecopy (Pientini)

(11) Double quantum filtered ¹H-¹H correlated spectroscopy (Piantini, U.; Sorenson, O. W.; Ernst, R. R. J. Am. Chem. Soc. 1982, 104, 6800).

(12) Two-dimensional nuclear Overhauser enhancement spectroscop (Jeener, J.; Meier, B. H.; Bachmann, P.; Ernst, R. R. J. Chem. Phys. **1979**, 71, 4546). Mixing times of 100 and 300 ms were used. NOESY cross peak volumes were converted to distances by the two spin approximation, using the cytidine H5-H6 distance of 2.45 Å for calibration



Figure 1. Structure of bleomycin A₅.

was clear from the DQF-COSY spectrum of the Zn·BLM complex that the octamer remained in a B-form conformation.¹³

Both minor groove binding and (partial) intercalation models have been proposed for DNA binding by the bithiazole and C-terminal substituent of BLM.^{7c,14} We also obtained data that support both models. Consistent with intercalative binding, upon admixture of Zn·BLM and DNA, we observed broadening and upfield shifting of the aromatic bithiazole (Bit 5, 0.18 ppm; Bit 5['], 0.52 ppm) and base-paired thymidine₄ and guanosine₂ imino protons (0.1 ppm).^{15,16} However, the data do not support a classical mode of intercalation, as the sequential connectivities of base and sugar protons in the NOESY spectrum were not disrupted (Figure 2).^{17,18} In addition to the lack of disruption of the NOE walk,^{15a,19} strong supportive evidence for groove binding derives from the finding of intermolecular NOEs (supplementary material, Figure 1 and Table 3) between Sp 3 and Bit 5 of BLM with adenosine₅ H2 in the minor groove (Figure 3).²⁰ Also, protons in the β -hydroxyhistidine (His α) and methyl valerate moieties (Val Me) had intermolecular NOEs to minor groove protons (cytidine₇ H4' and H5',5") (Figure 3). Some protons in the BLM metal binding domain were also shifted downfield, consistent with minor groove binding.^{15a,19}

Analysis of the intermolecular BLM-DNA NOEs21 allows placement of a folded BLM structure²² in the minor groove of d(CGCTAGCG)₂. Molecular dynamics calculations²³ suggest a possible structure for the Zn(II)·BLM A₅ complex that is fully consistent with the observed NMR-derived distance data (Figure

Agents 1992, 1, 89. (b) Wang, A. H. J. Curr. Opin. Struct. Biol. 1992, 2, 361-368.

(16) Upfield shifting (0.1 ppm) of the T₄ and G₂ imino protons was noted in spectra acquired in H₂O; this supports intercalation, since groove binders typically cause downfield shifts of imino protons (Feigon, J.; Denny, W. A.; Leupin, W.; Kearns, D. R. J. Med. Chem. **1984**, 27, 450.

(17) In B-DNA, the base (H8, H6) exhibits NOEs to its own and 5'-flanking sugar H1' and H2',2" protons, permitting the sequence connec-tivities to be defined (Wüthrich, K. NMR of Proteins and Nucleic Acids; Wiley: New York, 1986). Intercalators disrupt this walk by causing helical unwinding that increases the distance between base steps to ≥ 5 Å. See, e.g.: Liu, X. L.; Chen, H.; Patel, D. J. J. Biomol. NMR **1991**, 1, 323. (18) In fact, unlike Zn-BLM A₅, a (2-aminoethyl)bithiazole A₅ derivative

shown previously to bind strongly to DNA (Kross, J.; Henner, W. D.; Haseltine, W. A.; Rodriguez, L.; Levin, M. D.; Hecht, S. M. *Biochemistry* **1982**, 21, 3711) did disrupt the NOE walk at the thymidine₄-adenosine₅ step of the same octamer, consistent with intercalation.

(19) (a) Patel, D. J.; Shapiro, L. Biopolymers 1986, 25, 707. (b) Yoshida,

(19) (a) Fact, D. 2, Shapito, L. Biopointers **1900**, 29, (50) (10) Fostila, M.; Banville, D. L.; Shafer, R. H. *Biochemistry* **1990**, 29, (585). (20) The Sp $3-A_5$ H2 NOE was very weak at 35 °C but more intense at 15 °C. In contrast, the Bit $5-A_5$ H2 cross peak was relatively strong at 35 °C but was not resolved at 15 °C due to line broadening. Line broadening is consistent with the existence of more than one BLM conformation.

^{(1) (}a) Hecht, S. M. Acc. Chem. Res. **1986**, 19, 83. (b) Kozarich, J. W.; Stubbe, J. Chem. Rev. **1987**, 87, 1107.

⁽¹³⁾ The DQF-COSY spectrum had ${}^{3}J_{\text{H}'-\text{H}2'} > J_{\text{H}'-\text{H}2''}$ and readily apparent H2'-H3' couplings but weak H2''-H3' couplings. These features are typical of the C2'-endo sugar pucker in B-DNA (Kim, S. G.; Lin, L.; Reid, B. R. Biochemistry 1992, 31, 3564). (14) (a) Povirk, L. F.; Hogan, M.; Dattagupta, N. Biochemistry 1979, 18, 96. (b) Chen, D. M.; Sakai, T. T.; Glickson, J. D.; Patel, D. J. Biochemi Biophys. Res. Commun. 1980, 92, 197. (c) Hénichart, J.-P.; Bernier, J.-L.; Helbecque, N.; Houssin, R. Nucleic Acids Res. 1985, 13, 6703. (d) Kuwahara, J.; Sugiura, Y. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 2459. (15) (a) Wilson, W. D.; Li, Y.; Veal, J. M. Adv. DNA Sequence Specific Acaptat 1992, J. 89. (b) Wang, A. H. J. Curr. Onin Struct Biol 1992, 2



Figure 2. Expanded NOESY contour plot (300 ms mixing time, 35 °C in D₂O, pD 7.0, containing 20 mM NaCl) for Zn·BLM A_5 -d(CGCTAGCG)₂, correlating distance connectivities between base (H8,6) and sugar (H2',2") protons. The tracing outlines connectivities between base protons and 5'-flanking sugar H2" protons.



Figure 3. Schematic diagram showing the six intermolecular NOEs. Assignments: 1, C_7 H4'-His H α ; 2 C_7 H4'-Val Me; 3, C_7 H5',5''-Val Me; 4, T_4 H3'-Gul H6, H6'; 5, A_5 H2-Bit 5; 6, A_5 H2-Sp 3. It was not possible to distinguish between the two CH₃ groups of the methyl valerate moiety.

4), although this structure is almost certainly not unique.²⁴ BLM (light blue) is positioned in the minor groove of the octamer (red), with Zn(II) (gold) at a distance of 3.3 Å from cytidine₇ H4' (red ball), i.e., the atom abstracted to initiate DNA degradation.^{1,8} Hydrogen-bonding interactions (yellow arrows) are present between the cationic spermidine C-terminus and the phosphate and ribose oxygens and between the A-ring bithiazole N (Figure 1) and guanosine₆ NH₂.¹⁴ The metal binding domain occupies a widened minor groove²⁵ in the B-form duplex; Ala NH₂ is H-bonded to a DNA backbone oxygen.

Further studies employing other DNAs and BLMs are underway to allow us to test and refine this model.

Acknowledgment. This study was supported by Research Grant CA 53913 from the National Cancer Institute.

Supplementary Material Available: 2-D NMR spectrum highlighting the intermolecular BLM–DNA NOEs; tables showing ¹H chemical shifts for Zn·BLM A₅, d(CGCTAGCG)₂, and the Zn·BLM A₅–d(CGCTAGCG)₂ complex; and a correlation of the model to the NOE distance data (7 pages). This



Figure 4. Model of the Zn(II)·BLM A_5 -d(CGCTAGCG)₂ complex that satisfies the NOE restraints to within 0.2 Å. BLM (light blue) is positioned in the minor groove of the B-form octamer (red). The six intermolecular NOEs are shown as yellow lines; the apparent length difference is due to perspective only. H-bonding contacts are shown as yellow arrows pointing toward the hydrogen atoms. The metal ion (gold ball) is 3.3 Å from C₇ H4' (red ball).

material is contained in many libraries on microfiche, immediately follows this article in the microfilm version of the journal, and can be ordered from the ACS; see any current masthead page for ordering information.

(21) Because the individual duplex strands cannot be distinguished, there is an ambiguity in the assignments. Molecular modeling yielded lower energy structures using the strand-specific assignments shown in Figure 3. Also, Bit 5' appeared to show contacts to T₄ H6 and C₃ H6, which lie in the major groove. Although line broadening and spectral overlap make this assignment tentative, this may reflect a second binding mode for BLM. (22) An intramolecular NOE cross peak between His 2 and Thr Me requires the close ratial previous of these domains.

requires the close spatial proximity of these domains. (23) This model was developed using the Insight II/Discover program

(25) This model was developed using the histon in Discover program and the Biosym CVFF force field. Heme parameters provided with Insight II were used to model BLM-metal ion interaction. The five BLM ligands identified previously^{6e} were arranged around the metal in a square pyramid arrangement, with the Man carbamoyl as the axial ligand. Thirty starting structures were generated using the simulated annealing protocol (Nilges, M.; Clore, G. M.; Gronenborn, A. M. FEBS Lett. **1988**, 229, 317); of these, 18 structures with the lowest energies were minimized initially using 100 steps of a steepest descents algorithm and further using 30 000 steps of conjugate gradient minimization (178 NOE restraints, 23 distance restraints) to a final root mean square derivative of <0.001 kcal/mol/Å².

(24) Retention of DNA symmetry upon BLM binding and the small number and intensity of BLM–DNA NOEs suggest that the structure in Figure 4 is not unique. The bithiazole ring-current induced shifts noted, for example, could be accommodated by an additional structure in which the bithiazole is (partially) intercalated. In this regard, preliminary analysis of a Zn-BLM A₂-d(CGCTAGCG)₂ complex indicates the presence of a kinked DNA structure that may favor a (partial) intercalation binding mode.^{14c} The structure shown in Figure 4 represents the lowest energy structure consistent with both NMR-derived distance data and the known chemistry of BLM–DNA interaction.^{1.8} Two other low-energy structures that satisfy the NOE restraints to within 0.2 Å were also found. Both structures are groove binding models but differ from the structure shown in Figure 4 in that the H-bond from the bithiazole ring nitrogen to the 2-amino group of G₆ is not formed and the metal ion lies ca. 5.0 Å from C₇ H4'.

(25) An average minor groove width of 5.7 Å is anticipated for a B-form duplex (Conner, B. N.; Takano, T.; Tanaka, S.; Itakura, K.; Dickerson, R. E. *Nature* **1982**, 295, 294). In the model, minor groove widths range from 3.62 to 7.56 Å, with the metal binding domain occupying a minor groove width of 6.5-7.5 Å. Minor groove widths were measured as the shortest distances between sugar O4' atoms and phosphate P atoms across the groove. The O4'-O4' distances are decreased by 2.8 Å, or two oxygen van der Waals radii; those for P are decreased by 5.8 Å (Yuan, H.; Quintana, J.; Dickerson, R. E. *Biochemistry* **1992**, 31, 8009).